Preclinical development of immunotherapies

in vivo ADCC assay

© Antineo 2018

We perform in vivo ADCC (Antibody Dependent Cell Cytotoxicity) studies using cell lines and purified normal blood cell fractions. These may consist of total human leucocytes (Peripheral Blood Mononuclear Cells) from healthy donors or purified subpopulations (granulocytes, NK cells, T cells, monocytes). When the therapeutic antibody possesses ADCC activity, the antitumor efficacy of the compound in presence of blood cells is increased.